Axert almotriptan: Phase III data; NDA under review; marketed in Spain

In a 1,173-patient Phase III trial, 58 percent of patients given a single dose of 12.5 mg Axert had pain relief

Read the full 213 word article

How to gain access

Continue reading with a
two-week free trial.